Kromek Group PLC (AIM:KMK) shares rose 13% as the company announced it would report record revenues and positive EBITDA, surpassing market expectations.
The radiation and bio-detection technology leader experienced strong commercial momentum in the second half of the year, which was fuelled by multi-year contracts in advanced imaging and CBRN detection.
Improved gross margins and tight cost control further boosted performance for the 12 months ending April 30. Full-year results will be released in September 2024.
Kromek shares opened 0.89p higher at 7.64p.